Abstract

Olfactory neuroblastoma (ONB, Esthesioneuroblastoma) is an infrequent neoplasm of the head and neck area derived from olfactory neuroepithelium. Despite relatively good prognosis a subset of patients shows recurrence, progression and/or metastatic disease, which requires additional treatment. However, neither prognostic nor predictive factors are well specified. Thus, we performed a literature search for the currently available data on disturbances in molecular pathways, cytogenetic changes and results gained by next generation sequencing (NGS) approaches in ONB in order to gain an overview of genetic alterations which might be useful for treating patients with ONB. We present briefly ONB molecular pathogenesis and propose potential therapeutic targets and prognostic factors. Possible therapeutic targets in ONB include: receptor tyrosine kinases (c-kit, PDGFR-b, TrkB; EGFR); somatostatin receptor; FGF-FGFR1 signaling; Sonic hedgehog pathway; apoptosis-related pathways (Bcl-2, TRAIL) and neoangiogenesis (VEGF; KDR). Furthermore, we compare high- and low-grade ONB, and describe its frequent mimicker: sinonasal neuroendocrine carcinoma. ONB is often a therapeutic challenge, so our goal should be the implementation of acquired knowledge into clinical practice, especially at pretreated, recurrent and metastatic stages. Moreover, the multicenter molecular studies are needed to increase the amount of available data.

Highlights

  • Olfactory neuroblastoma (ONB) is a rare malignant tumor of the superior nasal cavity that was described for the first time in 1924

  • In this review article we report about main genetic disturbances, their correlation with prognosis, we describe concepts of molecular pathogenesis and potential targetable pathways in ONB

  • Bcl-2 acts as an anti-apoptotic factor and contributes to the HIF‐1a/Epo/erythropoietin receptor (EpoR)/Bcl‐2 system involved in angiogenesis [23]. hASH1 activates BCL-2 transcription, so Bcl-2 inhibitors are promising candidates for treatment of high-grade ONB; blocking of hASH1 can potentially block Bcl-2 activity [24]

Read more

Summary

GENERAL INFORMATION

Olfactory neuroblastoma (ONB) is a rare malignant tumor of the superior nasal cavity that was described for the first time in 1924. Cisplatin-based chemotherapy, usually with etoposide, is an accepted mode of treatment in advanced, recurrent, especially high grade cases [10,11,12,13], and non-platinum schemes (irinotecan, docetaxel, doxorubicin, ifosfamide, vincristine) were described to be www.impactjournals.com/oncotarget effective [14]. In this review article we report about main genetic disturbances, their correlation with prognosis, we describe concepts of molecular pathogenesis and potential targetable pathways in ONB. This should stimulate clinical pathologists, geneticists and oncologists to develop a grading system which better reflects the mutational state of the tumor and to investigate druggable targets for specific therapy

MOLECULAR PATHOGENESIS
PROGNOSTIC AND PREDICTIVE FACTORS
CYTOGENETIC ALTERATIONS
Worse prognosis
SNP array karyotyping
GENOME SEQUENCING
POTENTIAL TARGETABLE PATHWAYS
FUTURE DIRECTIONS
Findings
CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call